|
The result was announced after market hours yesterday, 10 May 2017.
Meanwhile, the S&P BSE Sensex was up 62.87 points or 0.21% at 30,311.04. The S&P BSE Mid-Cap index was up 95.51 points, or 0.64% at 15,045.05.
On BSE, so far 67,000 shares were traded in the counter as against average daily volume of 7,391 shares in the past one quarter. The stock hit a high of Rs 466.95 in intraday trade so far, which is a record high for the counter. The stock hit a low of Rs 430.80 so far during the day. The stock hit a 52-week low of Rs 184 on 12 May 2016.
The mid-cap company has equity capital of Rs 15.12 crore. Face value per share is Rs 2.
Caplin Point's earnings before interest, taxation, depreciation and amortization (EBITDA) rose 116% to Rs 47.64 crore in Q4 March 2017 over Q4 March 2016. The company's EBITDA margin surged to 40% in Q4 March 2017 from 27% in Q4 March 2016.
Caplin Point on 8 May 2017 announced that the company has received the Establishment Inspection Report (EIR) from USFDA (United States Food and Drug Administration) for inspection carried out between 21 October 2016 to 27 October 2016, at its sterile injectable plant at Gummidopoondi, Tamil Nadu (TN).
Caplin Point Laboratories is a niche pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa. The company caters to a complete range of finished dosage forms.
|